Compare TransMedics Group Inc (TMDX) vs State Street SPDR S&P Homebuilders ETF (XHB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs State Street SPDR S&P Homebuilders ETF — how do they compare? TransMedics Group Inc trades at $77.5 (market cap $2.74B), while State Street SPDR S&P Homebuilders ETF trades at $95 (market cap $1.49B). The key difference: TransMedics Group Inc is the larger of the two by market cap, and TransMedics Group Inc is trading nearer its 52-week high, State Street SPDR S&P Homebuilders ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold TransMedics Group Inc for 24 Days and State Street SPDR S&P Homebuilders ETF for 33 Days on average.
| TMDX | XHB | |
|---|---|---|
Market Cap | $2.74B | $1.49B |
Volume | 949,331 | 2,445,587 |
Sector | Health | Broad Market / Factor |
52-Week High | $150.42 | $121.36 |
52-Week Low | $61.99 | $94.86 |
Typical Hold Time | 24 Days | 33 Days |
Enterprise Value | $3.13B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
XHB, the SPDR S&P Homebuilders ETF, trades at $94.99, showing minimal daily change. Technical indicators are predominantly bearish, with moving averages signaling a downtrend and oscillators neutral. The ETF tracks the homebuilding sector, which faces headwinds from high mortgage rates but shows potential from recent housing policy support and institutional interest.
The outlook for XHB is mixed, balancing sector challenges like rising rates against catalysts such as new housing legislation. Investment opportunity hinges on a housing market rebound, while risks include economic sensitivity and rate volatility. Investor sentiment is cautious but attentive to policy impacts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About State Street SPDR S&P Homebuilders ETF
XHB invests in the U.S. homebuilding industry and related sectors. It provides equal-weighted exposure to homebuilders, building products, and home improvement retailers like Home Depot, Lowe's, and Builders FirstSource.
Read more on XHB →
